1
|
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
17.30
|
2
|
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
|
Lancet
|
2009
|
8.73
|
3
|
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
|
Lancet Oncol
|
2012
|
5.82
|
4
|
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
|
Lancet Oncol
|
2011
|
5.06
|
5
|
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
|
J Clin Oncol
|
2012
|
3.90
|
6
|
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2012
|
3.89
|
7
|
Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study.
|
J Clin Oncol
|
2005
|
2.90
|
8
|
Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
|
Jpn J Clin Oncol
|
2003
|
2.64
|
9
|
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.
|
J Clin Oncol
|
2007
|
2.62
|
10
|
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
|
Clin Cancer Res
|
2010
|
2.48
|
11
|
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
|
J Clin Oncol
|
2012
|
2.44
|
12
|
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.
|
Int J Radiat Oncol Biol Phys
|
2005
|
2.19
|
13
|
Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer.
|
J Thorac Oncol
|
2015
|
2.17
|
14
|
Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer.
|
Clin Cancer Res
|
2009
|
2.12
|
15
|
Extrapulmonary small-cell carcinoma: a single-institution experience.
|
Jpn J Clin Oncol
|
2004
|
2.02
|
16
|
Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
|
J Thorac Oncol
|
2013
|
1.93
|
17
|
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
|
J Clin Oncol
|
2012
|
1.76
|
18
|
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.
|
Blood
|
2007
|
1.74
|
19
|
Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
|
J Nucl Med
|
2006
|
1.72
|
20
|
Primary pulmonary non-Hodgkin's lymphoma.
|
Jpn J Clin Oncol
|
2004
|
1.70
|
21
|
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
|
Eur J Cancer
|
2009
|
1.65
|
22
|
Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma.
|
Leuk Res
|
2006
|
1.60
|
23
|
The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.
|
Lung Cancer
|
2013
|
1.58
|
24
|
A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
|
Cancer
|
2006
|
1.56
|
25
|
Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.
|
Leuk Lymphoma
|
2007
|
1.53
|
26
|
Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer.
|
Breast Cancer Res Treat
|
2009
|
1.51
|
27
|
Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.
|
J Thorac Oncol
|
2009
|
1.50
|
28
|
Dry pleural dissemination in non-small cell lung cancer: prognostic and diagnostic implications.
|
Radiology
|
2011
|
1.46
|
29
|
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
|
Cancer
|
2012
|
1.44
|
30
|
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
|
Cancer
|
2007
|
1.42
|
31
|
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
1.41
|
32
|
Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.
|
J Clin Oncol
|
2013
|
1.40
|
33
|
The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.
|
Mol Cancer Ther
|
2012
|
1.37
|
34
|
Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters.
|
Head Neck
|
2012
|
1.30
|
35
|
Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
|
J Thorac Oncol
|
2011
|
1.30
|
36
|
Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.
|
Eur J Cancer
|
2005
|
1.28
|
37
|
High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
|
Histol Histopathol
|
2012
|
1.26
|
38
|
Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.
|
J Clin Oncol
|
2005
|
1.23
|
39
|
A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.
|
J Thorac Oncol
|
2012
|
1.23
|
40
|
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
|
Lung Cancer
|
2012
|
1.21
|
41
|
Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era.
|
J Thorac Oncol
|
2010
|
1.14
|
42
|
Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.
|
Eur J Nucl Med Mol Imaging
|
2013
|
1.14
|
43
|
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
|
Lung Cancer
|
2009
|
1.11
|
44
|
Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
|
Lung Cancer
|
2009
|
1.10
|
45
|
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
|
Lung Cancer
|
2012
|
1.09
|
46
|
Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
|
Clin Immunol
|
2007
|
1.08
|
47
|
New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.
|
Lung Cancer
|
2010
|
1.07
|
48
|
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
|
Lung Cancer
|
2013
|
1.06
|
49
|
Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.
|
Cancer Chemother Pharmacol
|
2011
|
1.04
|
50
|
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2005
|
1.04
|
51
|
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
|
Cancer Chemother Pharmacol
|
2005
|
1.04
|
52
|
Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
|
J Clin Oncol
|
2006
|
1.04
|
53
|
Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
|
Oncol Rep
|
2005
|
1.04
|
54
|
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.
|
Am J Clin Oncol
|
2004
|
1.04
|
55
|
Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
|
J Mol Diagn
|
2012
|
1.03
|
56
|
Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis.
|
Biochem Biophys Res Commun
|
2003
|
1.03
|
57
|
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
|
Lung Cancer
|
2010
|
1.02
|
58
|
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
|
Cancer Chemother Pharmacol
|
2007
|
1.02
|
59
|
Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer.
|
Clin Cancer Res
|
2004
|
1.01
|
60
|
Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
|
Ann Thorac Surg
|
2005
|
1.00
|
61
|
Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer.
|
Int J Radiat Oncol Biol Phys
|
2002
|
1.00
|
62
|
Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
|
Int J Cancer
|
2009
|
1.00
|
63
|
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
|
PLoS One
|
2013
|
0.99
|
64
|
Influence of nano-carrier architecture on in vitro siRNA delivery performance and in vivo biodistribution: polyplexes vs micelleplexes.
|
ACS Nano
|
2011
|
0.98
|
65
|
Lung cancer working group report.
|
Jpn J Clin Oncol
|
2010
|
0.98
|
66
|
Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years.
|
Lung Cancer
|
2010
|
0.97
|
67
|
Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications.
|
Radiology
|
2012
|
0.97
|
68
|
Aggressive natural killer cell leukemia: clinical features and treatment outcome.
|
Haematologica
|
2002
|
0.97
|
69
|
A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
|
Oncology
|
2011
|
0.97
|
70
|
Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung.
|
Anticancer Res
|
2009
|
0.97
|
71
|
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
|
Clin Cancer Res
|
2008
|
0.97
|
72
|
Intestinal lymphoma: exploration of the prognostic factors and the optimal treatment.
|
Leuk Lymphoma
|
2004
|
0.97
|
73
|
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations.
|
Hum Genet
|
2011
|
0.96
|
74
|
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
|
Cancer
|
2008
|
0.96
|
75
|
Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies.
|
Am J Hematol
|
2002
|
0.95
|
76
|
L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms.
|
Int J Biochem Cell Biol
|
2004
|
0.94
|
77
|
Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer.
|
J Thorac Oncol
|
2013
|
0.94
|
78
|
Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.
|
Korean J Radiol
|
2010
|
0.93
|
79
|
Three cases of synchronous solid tumor and multiple myeloma.
|
Cancer Res Treat
|
2004
|
0.93
|
80
|
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
|
Lung Cancer
|
2010
|
0.93
|
81
|
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.
|
BMC Cancer
|
2011
|
0.92
|
82
|
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
|
Cancer Chemother Pharmacol
|
2004
|
0.92
|
83
|
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
|
Lung Cancer
|
2012
|
0.91
|
84
|
Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy.
|
J Cancer Res Clin Oncol
|
2011
|
0.91
|
85
|
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
|
J Thorac Oncol
|
2009
|
0.90
|
86
|
Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.
|
Lung Cancer
|
2009
|
0.90
|
87
|
Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy.
|
J Thorac Oncol
|
2010
|
0.90
|
88
|
Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy.
|
Ann Surg Oncol
|
2014
|
0.90
|
89
|
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.90
|
90
|
Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma.
|
Ann Hematol
|
2006
|
0.90
|
91
|
The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma.
|
Med Oncol
|
2008
|
0.90
|
92
|
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
|
Cancer Chemother Pharmacol
|
2006
|
0.90
|
93
|
Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity.
|
Invest New Drugs
|
2010
|
0.90
|
94
|
Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.
|
J Cell Biochem
|
2005
|
0.89
|
95
|
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
|
Invest New Drugs
|
2008
|
0.89
|
96
|
ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
|
Lung Cancer
|
2012
|
0.89
|
97
|
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
|
J Cancer Res Clin Oncol
|
2010
|
0.89
|
98
|
Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.
|
Oncology
|
2009
|
0.89
|
99
|
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
|
J Thorac Oncol
|
2014
|
0.89
|
100
|
EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey.
|
J Thorac Oncol
|
2015
|
0.88
|
101
|
Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.88
|
102
|
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
|
Cancer Chemother Pharmacol
|
2007
|
0.88
|
103
|
Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer.
|
Lung Cancer
|
2006
|
0.88
|
104
|
Effects of transforming growth factor beta (TGF-beta) receptor on lung carcinogenesis.
|
Lung Cancer
|
2002
|
0.88
|
105
|
Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray.
|
Cancer
|
2010
|
0.88
|
106
|
Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging.
|
Biomaterials
|
2007
|
0.88
|
107
|
Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery.
|
Cancer Chemother Pharmacol
|
2014
|
0.87
|
108
|
Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery.
|
Lung Cancer
|
2012
|
0.87
|
109
|
High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer.
|
Yonsei Med J
|
2012
|
0.87
|
110
|
Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?
|
Lung Cancer
|
2009
|
0.87
|
111
|
L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.
|
J Cell Biochem
|
2004
|
0.87
|
112
|
The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma.
|
Haematologica
|
2006
|
0.87
|
113
|
STAT1 and Nmi are downstream targets of Ets-1 transcription factor in MCF-7 human breast cancer cell.
|
FEBS Lett
|
2005
|
0.86
|
114
|
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
|
Genomics
|
2013
|
0.86
|
115
|
Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells.
|
Oncol Rep
|
2006
|
0.86
|
116
|
Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer.
|
Am J Clin Oncol
|
2002
|
0.86
|
117
|
Positive positron emission tomography scan in sarcoidosis and two challenging cases of metastatic cancer. CASE 2. Hepatocellular carcinoma with metastasis to the breast.
|
J Clin Oncol
|
2005
|
0.85
|
118
|
Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
|
J Thorac Oncol
|
2010
|
0.85
|
119
|
High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: a clinicopathologic study of 18 cases in the Korean population.
|
Leuk Lymphoma
|
2006
|
0.85
|
120
|
Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons.
|
J Mol Diagn
|
2010
|
0.85
|
121
|
FDG PET/CT and mediastinal nodal metastasis detection in stage T1 non-small cell lung cancer: prognostic implications.
|
Korean J Radiol
|
2008
|
0.85
|
122
|
Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
|
Ann Hematol
|
2006
|
0.84
|
123
|
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.
|
Lung Cancer
|
2013
|
0.84
|
124
|
Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit.
|
Support Care Cancer
|
2010
|
0.84
|
125
|
A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.
|
J Thorac Oncol
|
2013
|
0.83
|
126
|
CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation.
|
Leuk Lymphoma
|
2006
|
0.83
|
127
|
Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA).
|
Med Oncol
|
2009
|
0.83
|
128
|
Mouse orthotopic lung cancer model induced by PC14PE6.
|
Cancer Res Treat
|
2006
|
0.83
|
129
|
Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.
|
Neoplasia
|
2007
|
0.83
|
130
|
Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer.
|
APMIS
|
2009
|
0.83
|
131
|
Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis.
|
Int J Oncol
|
2003
|
0.83
|
132
|
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
|
J Thorac Oncol
|
2015
|
0.83
|
133
|
Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy.
|
Lung Cancer
|
2009
|
0.83
|
134
|
Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified".
|
Ann Hematol
|
2008
|
0.83
|
135
|
Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
|
Cancer
|
2010
|
0.83
|
136
|
Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.83
|
137
|
Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?
|
Korean J Radiol
|
2012
|
0.82
|
138
|
Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography.
|
J Thorac Oncol
|
2011
|
0.82
|
139
|
High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.
|
J Transl Med
|
2014
|
0.82
|
140
|
Nongastric marginal zone B-cell lymphoma: analysis of 247 cases.
|
Am J Hematol
|
2007
|
0.82
|
141
|
Esophageal squamous cell carcinoma recurring as a solitary renal mass.
|
Cancer Res Treat
|
2004
|
0.82
|
142
|
Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute.
|
Med Oncol
|
2013
|
0.81
|
143
|
Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma.
|
Med Oncol
|
2008
|
0.81
|
144
|
Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system.
|
Lung Cancer
|
2013
|
0.81
|
145
|
Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck.
|
Oral Oncol
|
2011
|
0.81
|
146
|
Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment.
|
Cancer
|
2009
|
0.81
|
147
|
Cerebral involvement of metastatic thymic carcinoma.
|
J Neurooncol
|
2005
|
0.81
|
148
|
Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery.
|
J Korean Med Sci
|
2006
|
0.81
|
149
|
Monensin inhibits the growth of renal cell carcinoma cells via cell cycle arrest or apoptosis.
|
Int J Oncol
|
2003
|
0.81
|
150
|
A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.
|
Lung Cancer
|
2003
|
0.81
|
151
|
Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study.
|
Cancer Lett
|
2007
|
0.81
|
152
|
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
|
Cancer Chemother Pharmacol
|
2012
|
0.81
|
153
|
Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer.
|
Lung Cancer
|
2012
|
0.80
|
154
|
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
|
Cancer
|
2010
|
0.80
|
155
|
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
|
Oncology
|
2010
|
0.80
|
156
|
Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells.
|
Biochem Biophys Res Commun
|
2005
|
0.80
|
157
|
Monensin-mediated growth inhibition in acute myelogenous leukemia cells via cell cycle arrest and apoptosis.
|
Int J Cancer
|
2002
|
0.80
|
158
|
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
|
Cancer Chemother Pharmacol
|
2014
|
0.80
|
159
|
L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors.
|
APMIS
|
2009
|
0.80
|
160
|
Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
|
Acad Radiol
|
2012
|
0.80
|
161
|
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
|
Biol Blood Marrow Transplant
|
2005
|
0.80
|
162
|
Low-density lipoprotein-mimicking nanoparticles for tumor-targeted theranostic applications.
|
Small
|
2014
|
0.79
|
163
|
Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer.
|
Cancer Imaging
|
2014
|
0.79
|
164
|
Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2008
|
0.79
|
165
|
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.
|
Cancer Chemother Pharmacol
|
2014
|
0.79
|
166
|
Activation of Raf1 and the ERK pathway in response to l-ascorbic acid in acute myeloid leukemia cells.
|
Cell Signal
|
2005
|
0.79
|
167
|
A new KIT gene mutation in thymic cancer and a promising response to imatinib.
|
J Thorac Oncol
|
2013
|
0.79
|
168
|
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
|
Cancer Chemother Pharmacol
|
2015
|
0.78
|
169
|
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
|
Cancer
|
2010
|
0.78
|
170
|
Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
|
Oncology
|
2004
|
0.78
|
171
|
The effect of N/P ratio on the in vitro and in vivo interaction properties of PEGylated poly[2-(dimethylamino)ethyl methacrylate]-based siRNA complexes.
|
Macromol Biosci
|
2013
|
0.78
|
172
|
A Single Nucleotide Polymorphism in the Phospholipase D1 Gene is Associated with Risk of Non-Small Cell Lung Cancer.
|
Int J Biomed Sci
|
2012
|
0.78
|
173
|
Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?
|
Lung Cancer
|
2006
|
0.78
|
174
|
Tuberculosis in hematopoietic stem cell transplant recipients in Korea.
|
Int J Hematol
|
2004
|
0.78
|
175
|
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
|
Invest New Drugs
|
2014
|
0.78
|
176
|
Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients.
|
Pharmacogenomics
|
2015
|
0.78
|
177
|
Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type.
|
Clin Cancer Res
|
2007
|
0.78
|
178
|
CD4+CD56+CD68+hematopoietic tumor of probable plasmacytoid monocyte derivation with weak expression of cytoplasmic CD3.
|
J Korean Med Sci
|
2002
|
0.78
|
179
|
Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer.
|
Lung Cancer
|
2007
|
0.78
|
180
|
Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats.
|
Cancer Chemother Pharmacol
|
2010
|
0.78
|
181
|
Pulmonary complications after hematopoietic stem cell transplantation.
|
J Korean Med Sci
|
2006
|
0.77
|
182
|
Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland.
|
J Oral Pathol Med
|
2011
|
0.77
|
183
|
A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors.
|
J Thorac Oncol
|
2015
|
0.77
|
184
|
Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience.
|
Lung Cancer
|
2006
|
0.77
|
185
|
Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.76
|
186
|
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).
|
Eur J Cancer
|
2012
|
0.76
|
187
|
Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma.
|
Cancer Res Treat
|
2007
|
0.75
|
188
|
Preoperative concurrent radiochemotherapy and surgery for stage IIIA non-small cell lung cancer.
|
J Korean Med Sci
|
2006
|
0.75
|
189
|
The MISSION: Impossible? No, the Journey Should Continue with Better Targeting!
|
J Thorac Oncol
|
2015
|
0.75
|
190
|
The outcomes of hypertransfusion in major ABO incompatible allogeneic stem sell transplantation.
|
J Korean Med Sci
|
2004
|
0.75
|
191
|
Adenocarcinoma of unknown primary site.
|
Korean J Intern Med
|
2002
|
0.75
|
192
|
Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma.
|
Eur J Haematol
|
2006
|
0.75
|
193
|
Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome.
|
Leuk Res
|
2006
|
0.75
|
194
|
The effectiveness of maintenance pharmacotherapies for non-small cell lung cancer.
|
Clin Med Insights Oncol
|
2012
|
0.75
|
195
|
Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model.
|
Cancer Res Treat
|
2009
|
0.75
|
196
|
Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer: Past, Present, and Hope for the Future.
|
Cancer Res Treat
|
2003
|
0.75
|
197
|
High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.
|
Anticancer Res
|
2013
|
0.75
|
198
|
Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer.
|
Jpn J Clin Oncol
|
2003
|
0.75
|
199
|
High Dose Radiation Therapy Concurrent with Chemotherapy in Locally Advanced Nasopharynx Cancer.
|
Cancer Res Treat
|
2003
|
0.75
|
200
|
Postremission therapy for acute myeloid leukemia in the first remission.
|
Leuk Lymphoma
|
2007
|
0.75
|
201
|
Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
|
Curr Opin Oncol
|
2017
|
0.75
|
202
|
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
|
Cancer Chemother Pharmacol
|
2009
|
0.75
|
203
|
The Relation between Histopathologic Findings on Surgical Specimen and Outcomes in Patients with N2 Positive Stage IIIA Non-Small Cell Lung Cancer Receiving Preoperative Concurrent Radiochemotherapy and Surgery.
|
Cancer Res Treat
|
2003
|
0.75
|
204
|
A Multi-Center, Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Cisplatin for Patients with Non-Small Cell Lung Cancer.
|
Cancer Res Treat
|
2003
|
0.75
|
205
|
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
|
Jpn J Clin Oncol
|
2005
|
0.75
|
206
|
Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
|
Jpn J Clin Oncol
|
2003
|
0.75
|
207
|
Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR.
|
Oncologist
|
2015
|
0.75
|
208
|
Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series.
|
Head Neck
|
2015
|
0.75
|
209
|
What is stage II in high-grade primary gastric lymphoma? How to define the range of "localized disease".
|
Leuk Res
|
2006
|
0.75
|
210
|
Rapid detection of exon 2-deleted AIMP2 mutation as a potential biomarker for lung cancer by molecular beacons.
|
Biosens Bioelectron
|
2013
|
0.75
|
211
|
Use of GCDFP-15 (BRST-2) as a Specific Immunocytochemical Marker for Diagnosis of Gastric Metastasis of Breast Carcinoma.
|
Cancer Res Treat
|
2003
|
0.75
|